Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by M. Baba
Total Records ( 5 ) for M. Baba
  F. Tarkanyi , S. Takacs , A. Hermanne , F. Ditroi , B. Kiraly , M. Baba , T. Ohtsuki , S. F. Kovalev and A. V. Ignatyuk
  The excitation function of the natEr(p,xn)165Tm reaction resulting in production of 165Er was measured up to 70MeV by activation of stacked foils practically for the first time. The theoretical interpretation is based on the results of the ALICE-IPPE and EMPIRE-II codes. From the measured experimental cross section data integral production yield was calculated and compared with experimental integral yield data reported in the literature. Different production routes of the therapeutic radioisotope 165Er were compared.
  F. Tarkanyi , A. Hermanne , B. Kiraly , S. Takacs , F. Ditroi , J. Csikai , A. Fenyvesi , M.S. Uddin , M. Hagiwara , M. Baba , T. Ido , Yu.N. Shubin and A.V. Ignatyuk
  Production cross-sections of 103Ag obtained by irradiating natPd and natCd with 70 MeV protons are presented and compared with ALICE-IPPE model calculations. Production of 103Ag is of interest for the generation of 103Pd widely used in brachytherapy. The investigated energy range of the 103Rh(d,2n)103Pd reaction was extended up to 40 MeV and the results were compared with the curves of ALICE-IPPE, EMPIRE-II and GNASH theoretical codes. Thick target yields were calculated. An overview and analysis of the most important charged particle induced production routes of 103Pd is presented. An explanation of the apparent discrepancy in the activity measurements for 103Rh based on X- or gamma-ray is given.
  J. Satoh , S. Yagihashi , M. Baba , M. Suzuki , A. Arakawa , T. Yoshiyama and S. Shoji
  Aims: To evaluate the efficacy, safety and pharmacokinetics of pregabalin in treating neuropathic pain associated with diabetic peripheral neuropathy in Japanese patients. Methods: A randomized, double-blind, placebo-controlled, multicentre 14 week clinical trial was conducted. Japanese patients with diabetic peripheral neuropathy (n = 317) were randomized to receive placebo or pregabalin at 300 or 600 mg/day. The primary efficacy measure was a change of mean pain score from baseline to end-point from patients’ daily pain diaries. Results: Significant reductions in pain were observed in patients treated with pregabalin at 300 and 600 mg/day vs. placebo (P < 0.05). Improvements in weekly pain scores were observed as early as week 1 and were sustained throughout the study period (300 and 600 mg/day difference from placebo at study end-point, -0.63 and -0.74, respectively). Pregabalin produced significant improvements in weekly sleep interference scores, the short-form McGill Pain Questionnaire, the Medical Outcomes Study-Sleep Scale, the 36-item Short-Form Health Survey scale, and the Patient and Clinical Global Impression of Change. Patient impressions of numbness, pain and paraesthesia were also significantly improved. Regarding treatment responders, 29.1 and 35.6% of patients treated with 300 and 600 mg/day, respectively, reported ≥50% improvement in mean pain scores (vs. 21.5% for placebo). Pregabalin was well tolerated; somnolence (26%), dizziness (24%), peripheral oedema (13%) and weight gain (11%) were the most common adverse events and generally were reported as mild to moderate. Conclusions: Pregabalin was effective in reducing pain and improving sleep disturbances due to pain, and was well tolerated in Japanese patients with painful DPN.
  N Hotta , R. Kawamori , Y. Atsumi , M. Baba , H. Kishikawa , J. Nakamura , S. Oikawa , N. Yamada , H. Yasuda and Y. Shigeta
  Aims  The long-term efficacy of epalrestat, an aldose reductase inhibitor, in improving subjective symptoms and nerve function was comprehensively assessed to identify patients with diabetic peripheral neuropathy who responded to epalrestat treatment.

Methods  Stratified analyses were conducted on data from patients in the Aldose Reductase Inhibitor-Diabetes Complications Trial (ADCT). The ADCT included patients with diabetic peripheral neuropathy, median motor nerve conduction velocity ≥ 40 m/s and with glycated haemoglobin (HbA1c) ≤ 9.0%. Longitudinal data on HbA1c and subjective symptoms of the patients for 3 years were analysed (epalrestat n = 231, control subjects n = 273). Stratified analyses based on background variables (glycaemic control, grades of retinopathy or proteinuria) were performed to examine the relationship between subjective symptoms and nerve function. Multiple logistic regression analyses were conducted.

Results  Stratified subgroup analyses revealed significantly better efficacy of epalrestat in patients with good glycaemic control and less severe diabetic complications. In the control group, no improvement in nerve function was seen regardless of whether symptomatic benefit was obtained. In the epalrestat group, nerve function deteriorated less or improved in patients whose symptoms improved. The odds ratio of the efficacy of epalrestat vs. control subjects was approximately 2 : 1 (4 : 1 in patients with HbA1c ≤ 7.0%).

Conclusion  Our results suggest that epalrestat, an aldose reductase inhibitor, will provide a clinically significant means of preventing and treating diabetic neuropathy if used in appropriate patients.

  M. Baba , T. Uba and A.R. Halim
  Pennisetum pedicellatum (kyasuwa) hay was ensiled with poultry litter in varying proportions; 80:20, 70:30, 60:40, 50:50 and 100:0 (control), respectively in polythene bags under room temperature for 21 days. The resultant silage was analyzed for pH, aroma, Crude Protein (CP), Crude Fiber (CF), Ether Extract (EE), ash and Nitrogen Free Extract (NFE). The result of the study indicated significant differences (p<0.05) among the treatments in terms of pH, aroma, CP, CF, NFE and ash but non significant differences in Dry Matter (DM) and EE. Ensiling with poultry litter increased pH, CP, DM and NFE while CF, ash and EE declined. CP and DM increased with increased proportion of poultry litter while CF and ash decreased. No definite trend was observed for pH, EE and NFE. Treatment 50:50 had the highest DM (93.18%) and CP (4.65%) while control recorded the least (CP 1.64%, DM 92.29%). Crude Fiber (CF) was lowest in treatment 50:50. It was concluded that ensiling kyasuwa hay with up to 50% poultry litter improved the feeding value of the silage significantly,
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility